Aurisco Pharmaceutical Co Ltd (605116) — Capital Reinvestment Ratio
Aurisco Pharmaceutical Co Ltd (605116) has a Capital Reinvestment Ratio of 1.63x as of December 2024, meaning it reinvests 2% of its operating cash flow (CN¥332.41 Million) in capital expenditures (CN¥540.28 Million). Check tangible equity quality of Aurisco Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Aurisco Pharmaceutical Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Aurisco Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see 605116 operating cash flow.
Annual Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd from 2017 to 2024. See 605116 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.63x | CN¥332.41 Million | CN¥540.28 Million | ▲ +105.2% |
| 2023 | 0.79x | CN¥385.61 Million | CN¥305.48 Million | ▼ -39.0% |
| 2022 | 1.30x | CN¥166.41 Million | CN¥216.23 Million | ▲ +4.5% |
| 2021 | 1.24x | CN¥201.57 Million | CN¥250.61 Million | ▲ +67.9% |
| 2020 | 0.74x | CN¥214.48 Million | CN¥158.80 Million | ▲ +83.8% |
| 2019 | 0.40x | CN¥179.90 Million | CN¥72.47 Million | ▼ -53.0% |
| 2018 | 0.86x | CN¥109.77 Million | CN¥94.14 Million | ▼ -5.1% |
| 2017 | 0.90x | CN¥117.91 Million | CN¥106.60 Million | — |